Icosavax_Logo.jpg
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 16:05 ET | Icosavax, Inc.
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial...
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
July 27, 2022 06:45 ET | BioNTech SE
NEW YORK and MAINZ, Germany, July 27, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind...
Pfizer und BioNTech treiben COVID-19-Impfstoffstrategie weiter voran: neue klinische Studie mit Impfstoffkandidaten der nächsten Generation mit verbessertem Design des Spike-Proteins begonnen
July 27, 2022 06:45 ET | BioNTech SE
NEW YORK und MAINZ, Deutschland, 27. Juli 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute den Beginn einer randomisierten, aktiv kontrollierten und...
Logo.png
Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing
July 14, 2022 08:00 ET | Cocrystal Pharma, Inc.
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that...
3.png
Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVID
July 14, 2022 07:00 ET | Panacea Life Sciences Holdings, Inc.
GOLDEN, Colo., July 14, 2022 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) (“Panacea” or the “Company”), a Colorado, USA-based cannabinoid research-focused company providing...
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
June 29, 2022 16:45 ET | BioNTech SE
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses NEW YORK and MAINZ, GERMANY, JUNE...
Pfizer und BioNTech schließen neue Liefervereinbarung mit der US-Regierung für zusätzliche Dosen des COVID-19-Impfstoffs
June 29, 2022 16:45 ET | BioNTech SE
Liefervereinbarung umfasst 105 Millionen 30 µg-, 10 µg- sowie 3 µg-Dosen, die bis einschließlich des vierten Quartals 2022 geliefert werden sollen; die US-Regierung hat die Option, 195 Millionen...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
June 25, 2022 10:02 ET | BioNTech SE
Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels;...
Logo 1.png
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
June 21, 2022 16:01 ET | Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
June 17, 2022 09:22 ET | BioNTech SE
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young...